Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q2 FY22 results · Jul–Sep 2021
Procter & Gamble Health reported revenue from operations of ₹272.80 crore (up 3.3% from Q2 FY21) and net profit of ₹55.37 crore (down 6.6% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a standalone basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 272.80 | 263.97 | +3.3% | 285.39 | −4.4% |
| Other income | 3.04 | 6.72 | −54.8% | 2.42 | +25.6% |
| Total income | 275.84 | 270.69 | +1.9% | 287.81 | −4.2% |
| Profit before tax | 74.07 | 77.22 | −4.1% | 43.53 | +70.2% |
| Net profit for the period | 55.37 | 59.26 | −6.6% | 33.89 | +63.4% |
| EPS, basic (₹) | 33.40 | 35.70 | −6.4% | 20.40 | +63.7% |
| Net margin (%) | 20.3 | 22.4 | 11.9 |
Standalone
- Filed with BSE
- 09 Nov 2021, 19:17 IST
- Board meeting
- 09 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE